ArticleInfection and immunity2005
Characterization of a novel leucine-rich repeat protein antigen from group B streptococci that elicits protective immunity.
Article in Infection and immunity, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 50 citations in OpenAlex.
- Surface protein distribution in Group B Streptococcus isolates from South Africa and identifying vaccine targets through in silico analysis.Scientific reports · 2024Article
- Insight into the Structure, Functions, and Dynamics of theMembranes · 2022Review
- Expression of a leptospiral leucine-rich repeat protein using a food-grade vector in3 Biotech · 2019Article
- Transcriptomic Analysis of Streptococcus pyogenes Colonizing the Vaginal Mucosa IdentifiesmBio · 2019Article
- Surface Structures of Group BMicrobiology spectrum · 2019Review
- Group B Streptococcal Colonization, Molecular Characteristics, and Epidemiology.Frontiers in microbiology · 2018Review
- Review
- Association and virulence gene expression vary among serotype III group B streptococcus isolates following exposure to decidual and lung epithelial cells.Infection and immunity · 2014Article
- The AgrD N-terminal leader peptide of Staphylococcus aureus has cytolytic and amyloidogenic properties.Infection and immunity · 2014Article
- Staphylococcus aureus SasA is responsible for binding to the salivary agglutinin gp340, derived from human saliva.Infection and immunity · 2013Article
- Transmission probabilities and durations of immunity for three pathogenic group B Streptococcus serotypes.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2011Article
- Virulence mechanisms of Tannerella forsythia.Periodontology 2000 · 2010Review
- DNA vaccines for targeting bacterial infections.Expert review of vaccines · 2010Review
- Streptococcus adherence and colonization.Microbiology and molecular biology reviews : MMBR · 2009Review
- Leucine-rich repeats of bacterial surface proteins serve as common pattern recognition motifs of human scavenger receptor gp340.The Journal of biological chemistry · 2009Article
- Surfome analysis as a fast track to vaccine discovery: identification of a novel protective antigen for Group B Streptococcus hypervirulent strain COH1.Molecular & cellular proteomics : MCP · 2009Article
- Heterologous production of methionine-gamma-lyase from Brevibacterium linens in Lactococcus lactis and formation of volatile sulfur compounds.Applied and environmental microbiology · 2009Article
- The promastigote surface antigen gene family of the Leishmania parasite: differential evolution by positive selection and recombination.BMC evolutionary biology · 2008Article
- Recent advances in understanding the molecular basis of group B Streptococcus virulence.Expert reviews in molecular medicine · 2008Review
- Streptococcus pneumoniae surface protein PcpA elicits protection against lung infection and fatal sepsis.Infection and immunity · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Group B streptococci (GBS) usually behave as commensal organisms that asymptomatically colonize the gastrointestinal and urogenital tracts of adults. However, GBS are also pathogens and the leading bacterial cause of life-threatening invasive disease in neonates. While the events leading to transmission and disease in neonates remain unclear, GBS carriage and level of colonization in the mother have been shown to be significant risk factors associated with invasive infection. Surface antigens represent ideal vaccine targets for eliciting antibodies that can act as opsonins and/or inhibit colonization and invasion. Using a genetic screen for exported proteins in GBS, we identified a gene, designated lrrG, that encodes a novel LPXTG anchored surface antigen containing leucine-rich repeat (LRR) motifs found in bacterial invasins and other members of the LRR protein family. Southern blotting showed that lrrG was present in all GBS strains tested, representing the nine serotypes, and revealed the presence of an lrrG homologue in Streptococcus pyogenes. Recombinant LrrG protein was shown in vitro to adhere to epithelial cells in a dose-dependent manner, suggesting that it may function as an adhesion factor in GBS. More importantly, immunization with recombinant LrrG elicited a strong immunoglobulin G response in CBA/ca mice and protected against lethal challenge with virulent GBS. The data presented in this report suggest that this conserved protein is a highly promising candidate antigen for use in a GBS vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.